FigsharePub Date : 2025-01-10DOI: 10.1021/acschemneuro.4c00717.s001
Sijing Li (1623253), Lin Wu (153444), Juan Xie (461923), Guijuan Zhou (591192), Xuanwei Wen (20539963), Limin Deng (5315435), Shudong Lin (1821334), Guozhi Liu (9977970), Shuangxi Chen (7009001), Zijian Xiao (591185)
{"title":"Edaravone ImprovesnMotor Dysfunction Following BrachialnPlexus Avulsion Injury in Rats","authors":"Sijing Li (1623253), Lin Wu (153444), Juan Xie (461923), Guijuan Zhou (591192), Xuanwei Wen (20539963), Limin Deng (5315435), Shudong Lin (1821334), Guozhi Liu (9977970), Shuangxi Chen (7009001), Zijian Xiao (591185)","doi":"10.1021/acschemneuro.4c00717.s001","DOIUrl":"https://doi.org/10.1021/acschemneuro.4c00717.s001","url":null,"abstract":"Brachial plexus root avulsion (BPRA) is often causednby road collisions,nleading to total loss of motor function in the upper limb. At present,neffective treatment options remain limited. Edaravone (EDA), a substancenthat eliminates free radicals, exhibits numerous biological properties,nincluding neuroprotective, antioxidant and anti-inflammatory effects.nHowever, the specific role and molecular mechanisms of EDA in thentreatment of BPRA remain to be fully elucidated. The present studynused a rat model of BPRA, following avulsion of the fifth, sixth andnseventh cervical (C5, C6 and C7) anterior roots. Notably, C6 was replantednfollowing a subcutaneous injection of either saline or 30 mg/kg/daynEDA for seven continuous days. Subsequently, behavioral, histochemical,nWestern blot and reverse transcription-quantitative PCR (RT-PCR) analysesnwere conducted. Results of the present study revealed that treatmentnwith EDA improves motor dysfunction, indicated by the increased Groomingntest score, usage of the affected limb, and Irvine, Beatties and Bresnahann(IBB) score, following BPRA. In addition, EDA reduced the death ofnmotoneurons (MNs), indicated by the increased number of Nissl-positivenneuron, at the site of the affected limb, inhibited neuroinflammationnand cellular pyroptosis, indicated by the decreased expression levelsnof IL-1β, IL-6, TNF-α, IL-18, p-p65, NLRP3, GSDMD andnCaspase-1, improved the morphology of the abnormal myocutaneous nervenfibers, promoted axon remyelination, indicated by increased mRNA expressionnlevels of remyelination-associated genes, including egr2, GAP-43,nhmgcr, L1CAM, mpz, pmp22 and prx and demyelination-associated genes,nincluding ngfr, notch1, pou3f1 and sox2, and alleviated muscle atrophy,nindicated by the increased weight and volume of biceps brachii muscle,nand the decreased number of fibroblasts and increased diameters innthe fibers. Collectively, results of the present study suggested thatnEDA may support axonal remyelination and inhibit pyroptosis-associatednneuroinflammation, enhancing MN survival and facilitating functionalnmotor recovery. Thus, the present study may provide a novel theoreticalnbasis for the use of EDA in the treatment of BPRA.","PeriodicalId":521695,"journal":{"name":"Figshare","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147884186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}